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In this study, an assessment of the efficacies, potencies and qualities of 11 brands of 5 different 
antibiotics including 3 brands of ampiclox and 2 brands each of ciprofolxacin, gentamicin, rifampicin 
and tetracylcine sold in Calabar, South-South region of Nigeria was carried out using the agar diffusion 
technique (sensitivity testing). The efficacies, potencies and qualities of these antibiotics were tested 
against some clinical isolates which include Escherichia coli, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Staphylococcus aureus and Streptococcus pyogenes in vitro. The overall mean zones of 
inhibition for the test organisms ranged from 33.0 – 34.7 mm, with 33 mm for E. coli, 20.9 mm for K. 
pneumoniae, 34.7 mm for P. aeruginosa, 31.4 mm for S. aureus and 17.6 mm for S. pyogenes. The result 
showed that 3 (60%) of the antibiotics (alaclox, ciprofloxacin and rifampicin) tested showed lower 
potency against the test organisms compared with the standard controls. Alaclox produced 
significantly (P < 0.05) lower zones of inhibition compared to the other brands of ampiclox (superclox 
and vitaclox) on S. aureus and S. pyogenes. However, significant differences (P = 0.007, P = 0.026, P = 
0.050, P = 0.012) were observed between the zones of inhibition of the test antibiotics and standard 
controls for the 3 brands of ampiclox tested on all the test organisms except for K. pneumoniae. There 
were also significant differences (P = 0.038, P = 0.038, P = 0.049, P = 0.025, P = 0.032) between the zones 
of inhibition observed for ciprofloxacin and their standard controls. Both brands of rifampicin (vitals 
and medifampi) produced significantly (P = 0.020, P = 0.038) lower zones of inhibition on E. coli and S. 
pyogenes compared to their standard controls. Our result also showed there were no significant 
differences (P > 0.05) between the observed zones of inhibition and standard controls of the brands of 
gentamicin (richem) and tetracycline. These overall and mean potencies of the test antibiotics showed 
differences in their efficacies, potencies and qualities. This confirmed that some brands of ampiclox, 
ciprofloxacin and rifampicin antibiotics sold in Nigeria do not contain the acclaimed quantity of active 
ingredients to exert bacteriocidal or bacteriostatic effect on common pathogens.  
 
Key words: Antibiotics, assessment, bacteriological quality, efficacy, potency, zones of inhibition. 






The present day use of the term antibiotics was proposed 
by Naksman in 1945 as those chemical substances of 
microbial origin which in small amounts exert anti-
microbial activity (Okonko et al., 2008). Antibiotics are 
usually of microbial origin but some have come from 
higher forms of life and chemotherapeutic agents made 
synthetically. Their selective toxicity means a low toxicity 
for host cells and high toxicity for parasites (Melmon and 
Morcelli, 1989). For an antibiotic to be effective, it exhibits 
selective toxicity and has a high therapeutic index. High 
therapeutic index implies a high ratio of maximum dose at 
which the antibiotics can be tolerated to a minimum dose 
required to cure infections. Such antibiotics do not 
eliminate the normal microbial flora of the host to avoid 
an upset of the balance of nature and prevent the readily 
development of resistant forms of these pathogens 
(Okonko et al., 2008).  
In the last few decades, antibiotics have been increa-
singly exploited by workers in a number of disciplines. 
For example, their usefulness in agriculture as plant 
protecting agents or for the promotion of animal growth 
and metabolic activities; in food industries as preser-
vatives and in basic biochemical research as specific 
inhibitors of metabolic pathways (processes) cannot be 
over emphasized (Florey, 1998). The major groups of 
antibiotics consist of families of chemically related 
substances with varying properties, some of which result 
from the natural manipulations of producing microbes and 
others from chemical alterations of the products of 
biosynthesis. The indiscriminate usage of these antibiotics 
influences its efficacy, resulting in resistance. It also 
leads to the growth of abnormal gut flora which inhibits 
proper digestion and assimilation of food. This undigested 
food putrefies and produces toxins that leads to the 
growth of yeast, fungal, bacterial and parasitic infections 
that damage the gut tissues. Amongst the more important 
beneficial bacterial destroyed by this indiscriminate usage 
include lactobacillus, Acidophilus and Bifidobacterium 
bitidus. It also affect many nutrients particularly the ones 
needed by the immune system to fight infection such as 
vitamins A and C. The sources in which antibiotics can be 
obtained include; microorganisms, synthesis and semi-
synthesis. Thus, antibiotics can be obtained from the 
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Abbreviations: ICU, Intensive care unit; HAIs, healthcare 
associated infections; ESBL, extended beta-lactamase; NA, 
nutrient agar, MCA, MacConkey agar; MSA, mannitol salt agar; 
MICs, minimal inhibitory concentrations; GNB, Gram-negative 
bacilli; MDR, multidrug resistant; UTIs, urinary tract infections; 
GMP, good manufacturing practices. 
and cephalosporins), bacteria-like Streptomyces spp., 
Bacillus spp., etc (example, rifampicin, aminoglycosides, 
chloramphenicol, erythromycin, tetracyclines).  
As the predominance of either the gram-positive or 
gram-negative bacteria isolates is influenced by 
geographical location and changes in time; so also is 
their antibiotic susceptibility pattern influenced by location 
and time (Nwadioha et al., 2010). Most bacteria exhibit 
remarkable versatility in their behaviour towards antibiotics 
and its capacity to produce human diseases had not 
diminished even with the introduction of antibiotics 
(Obiazi et al., 2007). A number of literatures indicated a 
gradual increase in the emergence of antibiotic-resistant 
microorganisms in hospitals (Suchitra and Lakshmidevi, 
2009). The changing patterns in the etiological agents of 
clinical pathogens and their sensitivities to commonly 
prescribed antibiotics are reported (Abubakar, 2009). 
High susceptibility of most pathogens to ampiclox and 
ciprofloxacin is an indication of effectiveness of the 
antibiotic against the bacteria (Doughari et al., 2007; 
Okonko et al., 2009a,b; Nkang et al., 2009a,b).  
Multi-drug resistance to gentamicin, rifampicin and 
tetracycline in equal magnitude in vitro has been reported 
and, as such, these antimicrobials may not be suitable for 
treating case of nosocomial or community acquired 
infection in this locality (Okonko et al., 2009a,b; Nkang et 
al., 2009b). Ciprofloxacin and gentamicin-resistant 
Pseudomonas spp., Klebsiella spp. and Escherichia coli 
was reported in a study by Jamshidi et al. (2009) in a 
study on the antimicrobial resistance pattern among 
intensive care unit patients. A previous study combining 
the data from 25 UK hospitals has shown that this 
microorganism is resistant to ofloxacin and ciprofloxacin 
in 59 and 62% of the cases, respectively (Jamshidi et al., 
2009). In their study, a change in the routine interventions 
used for empirical therapy of Staphylococcus aureus 
yielded a decline in resistance of this species against 
ciprofloxacin from 91.3 to 78.6%, suggesting that a 
modification of routine antimicrobial treatments can 
effectively alter the pattern of resistance of this pathogen 
to these drugs (Jamshidi et al., 2009). Resistance of 
intensive care unit (ICU)-acquired pathogens against 
ciprofloxacin can be attributed to its high usage in 
inpatient and outpatient settings (Jamshidi et al., 2009). 
E. coli sensitivity to ciprofloxacin and gentamycin was 
also reported by Nwadioha et al. (2010).  S. aureus 
resistant to cloxacillin, penicillin, ampicillin and tetracycline 
was reported by Obiazi et al. (2007) in Benin City, 
Nigeria. Although, outbreaks of S. aureus resistant to 
beta-lactam antibiotics have been frequently associated 
with devastating nosocomial infections (Depardieu et al., 
2007; Buhlmann et al., 2008), marked resistance to 
ampiclox which is a beta-lactam antibiotic by S. auerus 
has not been reported in recent studies (Obiazi et al., 





mycin and tetracycline among others with relatively 
higher susceptibility can be used for management of 
clinical conditions in our locality (Obiazi et al., 2007; 
Nkang et al., 2009a). Doughari et al. (2007) reported 
resistance rates of Salmonella isolates (92.3, 88.8, 79.6, 
53.5 and 20%) to amoxicillin, ampicillin, chloramphenicol, 
cotrimoxazole and ciprofloxacin, respectively. The 
implication of this high percentage resistance recorded 
for the antibiotics is that only amoxicillin and ciprofloxacin 
will effectively treat Salmonella typhi infections (Doughari 
et al., 2007; Nkang et al., 2009a). Filioussis et al. (2008) 
in their study reported Salmonella isolates that were 
resistant to several antimicrobials (tetracycline, trime-
thoprim/sulfamethoxazole, ampicillin and amoxicillin/ 
clavulanic acid), they found some susceptible to 
cefuroxime and ceftriaxone, as well as to nalidixic acid, 
ciprofloxacin and levofloxacin. A prominent reason for 
concern with regard to gastroenteritis-causing bacteria is 
the recognized emergence of antimicrobial resistance 
among key species.  
Some studies have shown Pseudomonas aeruginosa 
was 100% resistant to gentamicin, which was one of the 
antibiotics used for antimicrobial prophylaxis (Suchitra 
and Lakshmidevi, 2009). P. aeruginosa resistance to 
rifampicin and tetracycline has also been reported (Nkang 
et al., 2009b; Okonko et al., 2009a). P. aeruginosa and 
enterobacteriaceae species are the major cause of 
healthcare associated infections (HAIs), associated with 
significant morbidity and mortality (Jamshidi et al., 2009). 
They are also subjected to multi-drugs resistance (Jamshidi 
et al., 2009). Approximately, 2 - 10% of P. aeruginosa are 
resistant to all available treatments (Babay, 2007; 
Jamshidi et al., 2009). Reish et al. (1993) reported 
resistance of 55.6% to tetracycline by Klebsiella spp. 
Outbreak of multi-resistance Klebsiella was reported in 
neonatal intensive care unit in a hospital in Israel, 
Klebsiella isolates were resistant to gentamycin among 
others, but sensitive to quinolenes (Aiyegoro et al., 2007). 
Klebsiella pneumoniae isolates showed resistance to 
ciprofloxacin and amoxicillin/clavulanic acid was reported 
to be 55 and 12.5% in a study by Amin et al. (2009). 
There are reports covering high levels of resistance of K. 
pneumoniae towards these antibiotics in many countries. 
Moreover, limited use of these antibiotics is one of low 
levels of resistance towards K. pneumoniae (Amin et al., 
2009). Hsu et al. (2007) reported K. pneumoniae and E. 
coli to be resistant to ciprofloxacin in their study on 
antimicrobial drug resistance in Singapore Hospitals. 
Susceptibility to tetracycline by E. coli was reported by 
Aiyegoro et al. (2007) and Nkang et al. (2009b).  
In the last three decades, there have been a lot of 
reports in the scientific literature on the inappropriate use 
of antimicrobial agents and the spread of bacterial 
resistance among microorganisms causing infections 
(Abubakar, 2009). The emergence of antibiotic resistance 
in the management of most infections are serious public 
health issue, particularly in  the  developing  world  where  




apart from high level of poverty, ignorance and poor 
hygienic practices, there is also high prevalence of fake 
and spurious drugs of questionable quality in circulation. 
Much of the current discourse on infectious disease and 
drug resistance as it affects sub-Saharan Africa is limited 
to the pressing problems associated with emerging- and 
re-emerging resistant organisms. Resistance, however, 
equally compromises the management of acute respiratory 
infections, sexually transmitted diseases and diseases 
spread by the fecal-oral route, such as typhoid fever, 
cholera, dysentery and other diarrheal diseases (Okeke 
et al., 2007; Okonko et al., 2009b).  
The negative health and socioeconomic impact of 
indiscriminate usage of antibiotics and of fake drugs 
cannot be over emphasized. It is a common knowledge 
that some infections in Nigeria are becoming increasingly 
difficult to treat with the available antibiotics meant for it. 
These poor quality or sub standard drugs could be 
responsible for the increasing number of resistant strains 
of microorganisms in the country. The general concept 
here is that the active ingredients in these antibiotics may 
be less than what is indicated on the drugs and it calls for 
serious concern, because the quality of a drug is 
dependent on the correctness of its active ingredient 
(Immaculata and Abraham, 1990). The potencies of 
these antibiotics could also be affected by deterioration of 
the active ingredients due to expiration of the drugs and 
or storage conditions (Nnela and Cox, 1988). Further 
implication is that many bacterial and parasitic diseases 
that could, until recently, be treated with inexpensive 
antimicrobial agents, has recently been made more 
expensive and less successful by the emergence and 
spread of resistant organisms (Okeke et al., 2007; 
Okonko et al., 2009a,b). Bacterial resistance to beta-
lactam antibiotics is primarily due to the production of 
beta-lactam ring of the antibiotics rendering them inactive 
(Akpan, 1992). Resistance by microorganisms to 
antibiotics may be an indication of the presence of 
resistance factors such as R plasmids and enzymes such 
as beta-lactamases and of recent, extended beta-lacta-
mase (ESBL) (Doughari et al., 2007). The widespread use 
of broad-spectrum antibiotics has led to the emergence of 
nosocomial infections caused by drug resistant microbes 
(Chikere et al., 2008). Multidrug resistance and the 
presence of several virulence factors in the strains of 
many pathogens responsible for different diseases pose 
an increasing threat to the successful management of 
disease scourge. Also, the rising prevalence of drug 
resistance such as penicillin-resistant pneumococci 
worldwide, mandates selective susceptibility testing and 
epidemiological investigations during outbreaks (Okonko 
et al., 2008). However, strategies for addressing anti-
microbial drug resistance stress the need for new drugs 
(WHO, 2001) and yet the rate of drug development is in 
decline (Metlay et al., 2006). 
Knowledge of etiological agents of infections and their 
sensitivities to available drugs is of immense value to  the  




rational selection and use of antimicrobial agents and to 
the development of appropriate prescribing policies. The 
changing spectrum of microorganisms causing infections 
and the emerging resistance to many of the older and 
cheaper antibacterial agents require continuous monitoring 
(Abubakar, 2009). We believe that regular monitoring of 
the pattern of resistance of common pathogens in the 
hospitals and the assessment of the efficacies, potencies 
and qualities of antibiotics sold in a particular area is 
critical in planning the best routines for empirical treatment 
of infectious patients. This study therefore, reports the 
assessment of the efficacies, potencies and qualities of 
some of the antibiotics sold in Calabar, South-South 
region of Nigeria based on their brands or manufacturers; 








The study area was Calabar, Cross River State, South-South region 
of Nigeria. Calabar is one of the most ancient, colonial and cosmo-





All the chemicals and reagents used were of analytical grade, 
obtained from Sigma chemical co. Ltd, England. Media used in this 
study included: Nutrient agar (NA), Mac Conkey agar (MCA), blood 
agar, Mueller-Hinton Agar and Mannitol salt agar (MSA). All media 
were prepared according to the manufacturer’s specification and 
sterilized at 121°C for 15 min at 15 lb pressure. Clinical isolates 
used in this study were obtained from Microbiology Section of the 
Sufat Medical Laboratories, Ishie, Calabar; the Microbiology laboratory 
of the University of Calabar Teaching Hospital (UCTH) and the 
Department of Microbiology, University of Calabar, respectively. 
Isolations were also made from the clinical samples such as blood 
(for blood culture), urine, pus swab, wound swab and sputum 
collected from the above laboratories. All the samples and the test 
organisms were replicated on different media and the plates were 
then incubated at 37°C for 24 - 48 h. 
Discrete colonies were sub-cultured into fresh agar plates aseptically 
to obtain pure cultures of the isolates. Colonies identifiable as 
discrete on the Mueller Hinton agar were carefully examined 
macroscopically for cultural characteristics. All isolates were gram 
stained to determine their gram reaction. Biochemical tests were 
carried out as described by Jolt et al. (1994). The isolates were 
identified by comparing their characteristics with those of known 
taxa, as described by Jolt et al. (1994), Cheesbrough (2006) and 
Oyeleke and Manga (2008).  
 
 
Antibiotic susceptibility testing 
 
The test antibiotics used in this study were 3 brands of ampiclox (10 
mcg), and 2 brands each of ciprofloxacin (10 mcg), gentamicin (10 
mcg), rifampicin (10 mcg) and tetracylcine (25 mcg) as shown in 
Tables 1 to 6. The test antibiotics were bought from reputable 
pharmacy stores located within Calabar metropolis. Standard antibiotic 
sensitivity disks were also purchased from scientific supply stores in 
the Calabar metropolis. Whatman No.1 filter papers were obtained 





These were wrapped in foil paper and sterilized in the oven at 
160°C for 1 h. The sensitivity disks were prepared to the National 
Committee for Clinical Laboratory Standards and guidelines 
(NCCLS, 2002) to contain the concentrations 25 and 10 mcg 
equivalent to the standards. The different brands of the antibiotics 
were diluted to obtain the concentrations of the commercial 
standard disks using sterile distilled water. In order to get 25 mcg 
from 250 mg of the antibiotic, 250 mg of the antibiotic was 
converted to 250000 mcg. This was dissolved in 10 ml of sterile 
distilled water. This gave 25000 mcg and a 1: 10 dilution was 
prepared which gave 2500 mcg concentration. The 100 sensitivity 
disks already sterilized were put into the above solution. Each disk 
will absorb 25 mcg of the drug. In order to get 10 mcg from 500 mg 
of the antibiotic, 500 mg was converted to 500,000 mcg. This was 
also dissolved in 5 ml of sterile distilled water which gave 100,000 
mcg concentrations and a 1: 100 dilution was prepared to give 1000 
mcg. One hundred disks were each soaked with 1 ml containing 10 
mcg of the antibiotic. 
 
 
Activities of the antibiotics against the test organisms  
 
The antibiotic susceptibility patterns of the isolates to common 
antibiotics sold in Calabar were evaluated using the Kirby Bauer 
disc diffusion technique (Bauer et al., 1996) and 0.5 MacFarland’s 
10
8
/ml employed in inoculum suspensions preparation according to 
the recommendations of the National Committee for Clinical 
Laboratory Standards (NCCLS) and Clinical and Laboratory 
Standards Institute (CLSI) (NCCLS, 2002; CLSI, 2006; Okonko et 
al., 2009a, b). Mueller-Hinton agar (Difco Laboratories, Michigan, 
USA) is the NCCLS recommended medium for sensitivity analysis. 
It is an ideal medium for routine antimicrobial susceptibility tests 
since it shows good batch-to-batch uniformity and is low in 
tetracycline and sulfonamide inhibitors (Cheesbrough, 2006). 
Trypticase soy broth (BBL™ Trypticase™ Soy Broth, BIOTECH) 
was prepared. Five discrete colonies of the different identified 
isolates were inoculated into 5 ml of the broths and incubated at 
35°C for 4-6 h. The inoculum for primary sensitivity testing was 
prepared from a broth that has been incubated for 4-6 h. The 
density of the suspension was adjusted by adding the bacterial 
suspension to a sterile saline tube to match the density of the 
desired 0.5 McFarland standard. Each of the isolates was uniformly 
and aseptically inoculated into a different Mueller-Hinton agar 
plates by spread plate method using sterile cotton wool.  
These discs include ampiclox, ciprofloxacin, gentamicin, rifampicin 
and tetracylcine and were tested against the isolates. The antibiotic 
sensitivity test was performed by disc diffusion technique using 
commercially available discs on Mueller Hinton agar plates (Iroha et 
al., 2009). The appropriate antibiotic discs were aseptically placed 
on the agar using sterile forceps. The plates were then incubated at 
37°C for 24 h. Interpretation of results was done using the zones of 
inhibition sizes (Cheesbrough, 2006; Okonko et al., 2009a, b).  
 
 
Preparation of the control sensitivity disks  
 
The method described by Pratt and Fekety (1986) was used. In this 
method, the sterilized filter paper disks were impregnated with the 
various dilutions (l0 and 25 mcg) of the test antibiotics in duplicates. 
With the aid of a sterile forceps, the impregnated disks were 
carefully placed on the inoculated plates and firmly pressed unto 
the agar with the sterile forceps to ensure complete contact with the 
agar. The disks were distributed evenly at 24 mm distance and in a 
manner as to be no closer than 15 mm from the edge of the Petri 
dish. The standard antibiotic disks were also placed on separate 
plates seeded with the test organisms. The plates were covered 
with the tops, inverted and incubated immediately at 37°C for 24 h. 
The  standard  positive  commercial  disks  included  gram  positive,  




Table 1. Activities of the different brands of ampiclox against test organisms and their zones of inhibition.  
 
Code Test organism Brand 
Zones of inhibition (mm) Test statistics 
Test antibiotics Standard controls Mean + SE (n = 3) t- value P value 
I E. coli 
Alaclox (10 mcg) 32.0 40.0 
34.0 ± 1.15 -5.196 0.007* Superclox (10 mcg) 36.0 40.0 
Vitaclox (10 mcg) 34.0 40.0 
II K. pneumoniae 
Alaclox (10 mcg) 22.0 27.0 
24.7 ± 1.45 -1.606 0.184 Superclox (10 mcg) 27.0 27.0 
Vitaclox (10 mcg) 25.0 27.0 
III P. aeruginosa 
Alaclox (10 mcg) 34.5 44.0 
37.5 ± 1.89 -3.434 0.026* Superclox (10 mcg) 41.0 44.0 
Vitaclox (10 mcg) 37.0 44.0 
IV S. aureus 
Alaclox (10 mcg) 17.0 25.0 
20.2 ± 1.74 -2.778 0.050* Superclox (10 mcg) 23.0 25.0 
Vitaclox (10 mcg) 20.5 25.0 
V S. pyogenes 
Alaclox (10 mcg) 17.5 27.0 
20.5 ± 1.50 -4.333 0.012* Superclox (10 mcg) 22.0 27.0 
Vitaclox (10 mcg) 22.0 27.0 
 




Table 2. Activities of the different brands of ciprofloxacin against test organisms and their zones of inhibition.  
 
Code Test organism Brand 
Zones of inhibition (mm) Test statistics 
Test antibiotics Standard controls Mean + SE (n = 2) t- value P value 
I E. coli 
Ciprocin (10 mcg) 38.0 47.0 
39.5 ± 1.50 -5.000 0.038* 
Ciproxcin (10 mcg) 41.0 47.0 
II K. pneumoniae 
Ciprocin (10 mcg) 31.5 33.0 
31.8 ± 0.25 -5.000 0.038* 
Ciproxcin (10 mcg) 32.0 33.0 
III P. aeruginosa 
Ciprocin (10 mcg) 43.0 51.0 
44.5 ± 1.50 -4.333 0.049* 
Ciproxcin (10 mcg) 46.0 51.0 
IV S. aureus 
Ciprocin (10 mcg) 40.0 50.5 
38.0 ± 2.00 -6.250 0.025* 
Ciproxcin (10 mcg) 36.0 50.5 
V S. pyogenes 
Ciprocin (10 mcg) 30.0 39.0 
28.0 ± 2.00 -5.500 0.032* 
Ciproxcin (10 mcg) 26.0 39.0 
 




gram negative and broad spectrum disks while the negative control 
disks were impregnated with sterile distilled water. After incubation, 
the zones of clearance of organisms around the disks were also 
measured and recorded (NCCLS, 2002; Cheesbrough, 2006; 
Okonko et al., 2009a, b). An isolate was considered multi-drug 
resistant if it was resistant to at least three of the antibiotics tested 
(Santo et al., 2007). Quality control on the susceptibility discs were 
performed using laboratory strains of E. coli, P. aeruginosa, S. 





Data were analyzed using the general linear model procedure, 
analysis of variance (ANOVA) and independent t-test to compare 
the level of significant difference  between  the  test  antibiotics  and  





The different test organisms used in this study for 
assessment of efficacies, potencies and bacteriological 
qualities of some of the antibiotics sold in Nigeria include 
E. coli, K. pneumoniae, P. aeruginosa, S. aureus and 
Streptococcus pyogenes and the results presented in 
Tables 1 through 6. This indicated that efficacies, 
potencies and bacteriological qualities of these antibiotics 
sold in Nigeria differed depending on their brands or 
manufacturers. The sensitivity testing of the sensitivity 




Table 3. Activities of the different brands of gentamicin against test organisms and their zones of inhibition.  
 
Code Test organism Brand 
Zones of inhibition (mm) Test statistics 
Test antibiotics Standard controls Mean + SE (n = 2) t- value P value 
I E. coli 
Richem (10 mcg) 35.5 37.0 
34.3 ± 1.25 -2.200 0.159 
Shanghai (10 mcg) 33.0 37.0 
II K. pneumoniae 
Richem (10 mcg) 53.5 56.0 
51.8 ± 1.75 -2.249 0.136 
Shanghai (10 mcg) 50.0 56.0 
III P. aeruginosa 
Richem (10 mcg) 49.0 57.0 
47.5 ± 1.50 -6.333 0.024* 
Shanghai (10 mcg) 46.0 57.0 
IV S. aureus 
Richem (10 mcg) 45.0 49.0 
44.0 ± 1.00 -5.000 0.038* 
Shanghai (10 mcg) 43.0 49.0 
V S. pyogenes 
Richem (10 mcg) 06.0 10.0 
04.0 ± 2.00 -3.000 0.095 
Shanghai (10 mcg) 02.0 10.0 
 




Table 4. Activities of the different brands of rifampicin against  test organisms and their zones of inhibition. 
 
Code Test organism Brand 





Mean + SE (n = 
2) 
t- value P value 
I E. coli 
Vitals (10 mcg) 20.0 23.0 
19.5 ± 0.50 -7.000 0.020* 
Medifampi (10 mcg) 19.0 23.0 
II K. pneumoniae 
Vitals (10 mcg) 43.0 45.0 
41.8 ± 1.25 -2.600 0.122 
Medifampi (10 mcg) 40.5 45.0 
III P. aeruginosa 
Vitals (10 mcg) 09.0 12.0 
07.0 ± 2.00 -2.500 0.130 
Medifampi (10 mcg) 05.0 12.0 
IV S. aureus 
Vitals (10 mcg) 18.0 20.0 
17.5 ± 0.50 -5.000 0.038* 
Medifampi (10 mcg) 17.0 20.0 
V S. pyogenes 
Vitals (10 mcg) 27.0 29.5 
26.0 ± 1.00 -3.500 0.073 
Medifampi (10 mcg) 25.0 29.5 
 




Table 5. Activities of the different brands of tetracycline against test organisms and their zones of inhibition.  
 
Code Test organism Brand 
Zones of inhibition (mm) Test statistics 
Test antibiotics Standard controls Mean + SE (n = 2) t- value P value 
I E. coli 
Tetracap (25 mcg) 35.0 44.0 
37.5 ± 2.50 -2.600 0.122 
Tetrim (25 mcg) 40.0 44.0 
II K. pneumoniae 
Tetracap (25 mcg) 04.0 08.0 
05.0 ± 1.00 -3.000 0.095 
Tetrim (25 mcg) 06.0 08.0 
III P. aeruginosa 
Tetracap (25 mcg) 35.5 41.0 
36.8 ± 1.25 -3.400 0.077 
Tetrim (25 mcg) 38.0 41.0 
IV S. aureus 
Tetracap (25 mcg) 35.0 44.0 
37.5 ± 2.50 -2.600 0.122 
Tetrim (25 mcg) 40.0 44.0 
V S. pyogenes 
Tetracap (25 mcg) 08.0 13.0 
09.3 ± 1.25 -3.000 0.095 
Tetrim (25 mcg) 10.5 13.0 
 
SE = Standard error of mean. 




Table 6. Multiple responses of test organisms to different test antibiotics. 
 
Dependent variable (I) Brand grp (J) Brand grp Mean difference (I-J) + SE Significance 
E. coli 
  
Ampiclox  Ciprofloxacin -5.50 ± 1.99* 
-.250 ± 1.99 
14.50 ± 1.99* 








Ciprofloxacin Ampiclox  5.50 ± 1.99* 
5.25 ± 2.18 
20.00 ± 2.18* 








Gentamicin Ampiclox  0.25 ± 2.18 0.904 
Ciprofloxacin -5.25 ± 2.18 0.053 
Rifampicin  14.75 ± 2.18* 0.001 
Tetracycline -3.25 ± 2.18 0.187 
Rifampicin  Ampiclox  -14.50 ± 1.99* 0.000 
Ciprofloxacin -20.00 ± 2.18* 0.000 
Gentamicin -14.75 ± 2.18* 0.001 
Tetracycline -18.00 ± 2.18* 0.000 
Tetracycline Ampiclox  3.50 ± 1.99 0.130 
Ciprofloxacin -2.00 ± 2.18 0.395 
Gentamicin 3.25 ± 2.18 0.187 





















Ampiclox  Ciprofloxacin -7.08333* 0.008 
Gentamicin -27.08 ± 1.82* 0.000 
Rifampicin  -17.08 ± 1.82* 0.000 
Tetracycline 19.66667* 0.000 
Ciprofloxacin Ampiclox  7.08 ± 1.82* 0.008 
Gentamicin -20.00 ± 2.00* 0.000 
Rifampicin  -10.00 ± 2.00* 0.002 
Tetracycline 26.75 ± 2.00* 0.000 
Gentamicin 
 
Ampiclox  27.08 ± 2.00* 0.000 
Ciprofloxacin 20.00 ± 2.00* 0.000 
Rifampicin  10.00 ± 2.00* 0.002 
Tetracycline 46.75 ± 2.00* 0.000 
Rifampicin Ampiclox  17.08333* 0.000 
Ciprofloxacin 10.00 ± 2.00* 0.002 
Gentamicin -10.00 ± 2.00* 0.002 
Tetracycline 36.75 ± 2.00* 0.000 
Tetracycline Ampiclox  -19.66667* 0.000 
Ciprofloxacin -26.75000* 0.000 
Gentamicin -46.75 ± 2.00* 0.000 




Ampiclox   Ciprofloxacin -7.00 ± 2.40* 0.027 
Gentamicin -10.00 ± 2.40* 0.006 
Rifampicin  30.50 ± 2.40* 0.000 
Tetracycline 0.75 ± 2.40 0.766 




Table 6. contd. 
 









Ciprofloxacin Ampiclox  7.00 ± 2.40* 0.027 
Gentamicin -3.00 ± 2.63 0.298 
Rifampicin  37.50 ± 2.63* 0.000 





Ampiclox  10.00 ± 2.40* 0.006 
Ciprofloxacin 3.00 ± 2.63 0.298 
Rifampicin  40.50 ± 2.63* 0.000 





Ampiclox  -30.50 ± 2.63* 0.000 
Ciprofloxacin -37.50 ± 2.63* 0.000 
Gentamicin -40.50 ± 2.63* 0.000 





Ampiclox  -0.75 ± 2.63 0.766 
Ciprofloxacin -7.75000* 0.026 
Gentamicin -10.75 ± 2.63* 0.006 

























Ciprofloxacin -17.83 ± 2.39* 0.000 
Gentamicin -23.83 ± 2.39* 0.000 
Rifampicin  2.67 ± 2.39 0.307 





Ampiclox  17.83 ± 2.39* 0.000 
Gentamicin -6.00 ± 2.61 0.062 
Rifampicin  20.50 ± 2.61* 0.000 





Ampiclox  23.83 ± 2.39* 0.000 
Ciprofloxacin 6.00 ± 2.61 0.062 
Rifampicin  26.50 ± 2.61* 0.000 





Ampiclox  -2.67 ± 2.39 0.307 
Ciprofloxacin -20.50 ± 2.61* 0.000 
Gentamicin -26.50 ± 2.61* 0.000 





Ampiclox  17.33 ± 2.39* 0.000 
Ciprofloxacin -0.50 ± 2.61 0.855 
Gentamicin -6.50 ± 2.61* 0.048 
Rifampicin  20.00 ± 2.61* 0.000 
S. pyogenes Ampiclox  Ciprofloxacin -7.50 ± 2.19* 0.014 
  Gentamicin 16.50 ± 2.19* 0.000 
Rifampicin  -5.50 ± 2.19* 0.046 





Ampiclox  7.50 ± 2.19* 0.014 
Gentamicin 24.00 ± 2.40* 0.000 
Rifampicin  2.00 ±2.40 0.437 
Tetracycline 18.75  ± 2.40* 0.000 




Table 6. contd. 
 
Dependent variable (I) Brandgrp (J) Brandgrp Mean difference (I-J) + SE Significance 
S. pyogenes Gentamicin Ampiclox  -16.50 ± 2.19* 0.000 
Ciprofloxacin -24.00 ± 2.40* 0.000 
Rifampicin  -22.00 ± 2.40* 0.000 
Tetracycline -5.25 ± 2.40 0.072 
Rifampicin  Ampiclox  5.50 ± 2.19* 0.046 
Ciprofloxacin -2.00 ± 2.40 0.437 
Gentamicin 22.00 ± 2.40* 0.000 
Tetracycline 16.75 ± 2.40* 0.000 
Tetracycline Ampiclox  -11.25 ± 2.19* 0.002 
Ciprofloxacin -18.7 5± 2.40* 0.000 
Gentamicin 5.25 ± 2.40 0.072 
Rifampicin  -16.75 ± 2.40* 0.000 
 





testing of the test antibiotics were compared with that of 
the standardized commercial sensitivity disks which was 
analyzed using E. coli, S. aureus, P. aeruginosa, K. 
pneumoniae and S. pyogenes as presented in Tables 1 
to 6, respectively. The results obtained were interpreted 
using the measured diameter of the zones of inhibition 
shown by these antibiotics against the pathogens used. 
From Tables 2, 3, 4 and 5, there were no significant 
differences (P > 0.05) between the zones of inhibition and 
standard controls for the drugs tested against the test 
organisms.  
Activities of the different brands of ampiclox against  
test organisms and their zones of inhibition are shown in 
Table 1. It can be deduced that superclox showed a 
higher potency followed by vitaclox and alaclox when 
compared with the standard control. The result also 
showed that 1 (33.3%) of the ampiclox (alaclox) tested 
showed lower potency against the test organisms. In the 
same vein, superclox produced significantly (P < 0.05) 
higher zones of inhibition compared to the other brands 
of the drug (alaclox and vitaclox) on all test organisms 
except for S. pyogenes, in which superclox (22 mm) 
showed similar zones of inhibition with vitaclox (22 mm). 
Alaclox produced significantly (P < 0.05) lower zones of 
inhibition compared to the other drugs (superclox and 
vitaclox) on S. aureus and S. pyogenes. However, 
significant differences (P = 0.007, P = 0.026, P = 0.050, P 
= 0.012) were observed between the zones of inhibition 
of the test antibiotics and standard controls for the 3 
brands of ampiclox tested on all the test organisms 
except for K. pneumoniae. K. pneumoniae showed 
significantly (P = 0.184) high sensitivity to ampiclox 
comparable to the standard controls. 
Table 2 shows the activities of the different brands of 
ciprofloxacin against test organisms and their zones of 
inhibition. Ciproxcin produced significantly (P < 0.05) 
higher zones of inhibitions compared to ciprocin on all 
test organisms except for S. aureus (36 mm) and S. 
pyogenes (26 mm). Ciprocin produced significantly (P < 
0.05) higher zones of inhibition on S. aureus (40 mm) and 
S. pyogenes (30 mm). However, there were significant 
differences (P = 0.038, P = 0.038, P = 0.049, P = 0.025, 
P = 0.032) between the zones of inhibition of the test 
antibiotics and standard controls tested against the test 
organisms. 
Table 3 shows the activities of the different brands of 
gentamicin against test organisms and their zones of 
inhibition. Richem produced significantly (P < 0.05) higher 
zones of inhibitions compared to shanghai on all test 
organisms. However, there were no significant 
differences (P = 0.159, P = 0.136, P = 0.095) between 
the zones of inhibition and standard controls against the 
test organisms except for P. aeruginosa and S. aureus.  
Both brands produced significantly (P = 0.024, P = 
0.038) lower zones of inhibition on P. aeruginosa and S. 
aureus compared to the standard control. 
In Table 4, the activities of the different brands of 
rifampicin against test organisms and their zones of 
inhibition are shown. It can be deduced that vitals 
showed a higher efficacy than medifampi. Vitals 
produced higher zones of inhibition compared to 
medifampi on all test organisms, though it was not 
significant (P > 0.05). However, there were no significant 
differences (P = 0.122, P = 0.130, P = 0.073) between 
the zones of inhibition and standard controls for the drugs 
tested against the test organisms except for E. coli and S. 
pyogenes. Both brands produced significantly (P = 0.020, 
P = 0.038) lower zones of inhibition on E. coli and S. 
pyogenes compared to the standard controls.  
The activities of the different brands of tetracycline 
against test organisms and their zones of inhibition are 
shown in Table 5. It can also be inferred that tetrim 
showed a higher efficacy than tetracap on all the test 
organisms. However, there were no significant differences 




(P = 0.122, P = 0.095, P = 0.077, P = 0.122, P = 0.095) 
between the zones of inhibition and standard controls of 
the drugs tested against the test organisms. 
Table 6 shows the overall multiple responses of 
organisms of the test organisms to different test 
antibiotics. The overall mean zones of inhibition for the 
test organisms ranged from 33.0 – 34.7 mm, with 33 mm 
for E. coli, 20.9 mm for K. pneumoniae, 34.7 mm for P. 
aeruginosa, 31.4 mm for S. aureus and 17.6 mm for S. 
pyogenes. The multiple responses (LSD) of the test 
organisms to different antibiotics in terms of the 
effectiveness/efficacies of each test antibiotics compared 





The potency or activity per milligram of a chemothera-
peutic agent is usually expressed on the basis of the 
lowest concentration of minimal inhibitory concentrations 
(MICs) or higher zones of inhibition (Nnela and Cox, 
1988). In this study, an assessment of the efficacies, 
potencies and bacteriological qualities of 11 brands of 5 
different antibiotics sold in Nigeria was carried out 
including 3 brands of ampiclox and 2 brands each of 
ciprofolxacin, gentamicin, rifampicin and tetracylcine. 
From the results, the overall mean zones of inhibitions for 
the test organisms ranged from 33.0 – 34.7 mm, with 33 
mm for E. coli, 20.9 mm for K. pneumoniae, 34.7 mm for 
P. aeruginosa, 31.4 mm for S. auras and 17.6 mm for S. 
pyogenes. In this study, the potency of the standard 
drugs when compared to test antibiotics and the mean 
potency of the antibiotic on the organisms determined 
showed differences in efficacy and quality of the various 
brands of antibiotics sold in Nigeria. From our study, 
there were no significant differences (P > 0.05) between 
the zones of inhibitions of the test antibiotics and 
standard controls for some of the drugs tested against 
the test organisms while significant differences (P < 0.05) 
were observed between the zones of inhibitions of the 
test organisms and the standard controls for some other 
drugs tested against the test organisms.  
Our result showed there were no significant differences 
(P > 0.05) between the zones of inhibitions and standard 
controls for the brands of gentamicin (richem) and 
tetracycline. Gentamycin, a relatively cheap and an easily 
available antibiotic, is effective against the gram-negative 
bacilli (GNB) (E. coli and K. pneumonia) except for P. 
aeruginosa and effective against the grampositive cocci 
(GPC) [S. pyogenes] except for S. aureus in the study. 
This is similar to a study done in Calabar claiming 80% 
effectiveness (Martins et al., 2005) and a study done in 
Kano claiming 70.7 and 76.7% effectiveness against 
GNB and GPC, respectively (Nwadioha et al., 2010). 
Chikere et al. (2008) reported the sensitivities of GNB to 
gentamycin to be 100% and GPC  to  be  93.3%.  This  is  





of inhibitions reported for gentamicin and tetra-cycline in 
this study is contrary to the findings of some previous 
studies (Okonko et al., 2009b; Abubakar, 2009; Nkang et 
al., 2009a, b; Adedeji and Abdulkadir, 2009; Ullah et al., 
2009).  
Tetracycline is an antibiotic that inhibits bacterial growth. 
They are bacteristatic and widely used as a broad- 
spectrum antibiotic with activity against Gram- positive 
and Gram- negative bacteria. Resistance to tetracycline 
is common and this is further confirmed from the results 
obtained in a study by Adedeji and Abdulkadir (2009). 
Resistance to tetracycline has developed because it is 
readily available in the country and has been widely 
misused (Adedeji and Abdulkadir, 2009). Tetracycline 
resistant K. pneumoniae and S. pyogenes has been 
reported in our previous study (Nkang et al., 2009a, b). 
Okonko et al. (2009b) reported 100% resistance to 
gentamicin and tetracycline by K. pneumoniae, P. 
aeruginosa, E. coli, S. aureus and S. pyrogenes in a 
similar study. Abubakar (2009) reported high rate of 
resistance to tetracycline and gentamicin in their study. 
Tetracycline-resistant S. enterica Serovar Typhimurium 
and Eenteritidis was reported by Halawani and Shohayeb 
(2008). Recently, an epidemic multi-drug have emerged, 
presumably due to the extensive use of resistant strain 
serovar Typhimurium phage type 104 antimicrobial agents 
both in humans and animals (Halawani and Shohayeb, 
2008).  
Aminoglycosides have good activity against clinically 
important gram negative bacilli (Ullah et al., 2009). The 
aminoglycoside antibiotics include gentamcin, kanamycin, 
amikacin etc. These act by inhibiting bacterial protein 
synthesis. Among the non-β-lactams, gentamicin showed 
good activity with 48% isolates found susceptible in a 
study by Ullah et al. (2009), which is more than 29% 
recorded in Israel and 36% recorded in India (Colodner et 
al., 2007).This may be due to increased use of gentamicin 
in India and Israel as compared to Pakistan. Gentamycin 
is routinely used synergistically with a beta-lactam 
antibiotic or vancomycin for empirical therapy in infective 
endocarditis (Nwadioha et al., 2010). According to Ullah 
et al. (2009), pattern of resistance to aminoglycosides is 
affected by selective pressure in different regions. Ako-
Nai et al. (2005) presented a report in which 70.2% of 
staphylococcal isolates were resistant to tetracycline and 
1.8% to gentamycin in a study in Ibadan, Nigeria. Similar 
resistance profiles were presented among S. epidermidis 
in some hospitals in Turkey to be resistant to tetracycline 
(Abubakar, 2009). Gentamicin is the most commonly 
used aminoglycoside for serious urinary tract infections 
(UTIs) but it could have serious side effects such as 
damage to hearing, sense of balance and kidneys (Adedeji 
and Abdulkadir, 2009). The highest efficacy of gentamicin 
in the treatment of UTIs has also been reported by Al 
Sweih et al. (2005). 
The potency of the standard drugs  when  compared  to  





the organisms determined showed differences in efficacy 
and quality of the various brands of antibiotics sold in 
Nigeria. It also showed that 3 (60%) of the antibiotics 
(alaclox, ciprofloxacin and rifampicin) tested showed 
lower potency against the test organisms compared with 
the standard controls. This may reflect the fact that these 
are the most commonly prescribed antibiotics in the 
hospital and also the most easily available in the 
community without prescription and because they are 
also very cheap in terms of cost and so subject to abuse 
and misuse (Abubakar, 2009). The lower zones of 
inhibition reported for these 3 antibiotics in this study are 
contrary to what has been previously reported. Okonko et 
al. (2009b) reported 100% sensitivity to ciprofloxacin by 
K. pneumoniae, P. aeruginosa, E. coli, S. aureus and S. 
pyrogenes. Ciprofloxacin was 82.9% effective across all 
the bacterial isolates tested in vitro in a study by 
Nwadioha et al. (2010). Chikere et al. (2008) reported the 
sensitivities of GNB to ciprofloxacin to be 63.6%. 
Aiyegoro et al. (2007) reported 77.8% sensitivity to cipro-
floxacin. This is contrary to our present findings in which 
lower zones of inhibition was reported for ciprofloxacin. 
Ampiclox is a broad-spectrum penicillin, which is active 
against Gram- positive bacteria such as Streptococcus 
sp. and S. aureus but inactive against E. coli in up to 25% 
of cases. It is very clear from the results obtained in this 
study as well as in similar studies in Kuwait (Al Sweih et 
al., 2005) that most pathogens have acquired resistance 
to this antibacterial agent. Zones of inhibition shown by 
rifampicin tested against E. coli and S. aureus isolates 
were significantly lower. This is a clear indication that the 
isolated organisms have developed resistance to the 
antibiotic. Resistance of S. aureus to rifampicin has also 
been reported in Calabar (Nkang et al., 2009b). Fluoro-
quinolones are antibiotics which act by inhibiting the 
activity of DNA gyrase and topoisomerase, enzymes 
essential for bacterial DNA replication. These include 
ciprofloxacin, ofloxacin, enoxacin, sparfloxacin etc (Ullah 
et al., 2009). Ciprofloxacin is a member of the quinolones 
which are effective against a wide range of organisms 
(Cheesbrough, 2006). At the present time, the cost of 
obtaining this antibiotic is quite high and because of this, 
fewer number of people have access to it, thus, 
diminishing the chances of its misuse and of organisms 
developing resistance to it. Ciprofloxacin has been 
recommended as first line therapy in urinary tract 
infection (Ullah et al., 2009). Ciprofloxacin is not routinely 
recommended for pediatric use except in special cases 
where the benefits out – weigh the short term risk of joint 
toxicity, such as in cystic fibrosis (Nwadioha et al., 2010). 
But resistance to flouroquinolones is increasing 
throughout the world. The observed resistance in E. coli 
to ciprofloxacin was 62% in a study by Ullah et al. (2009). 
Higher percentages have been reported in other studies 
from Palestine, Canada, USA and Turkey (Yuksel et al., 
2006). 
Our result also showed that alaclox brand of the ampiclox 




tested showed lower potency against the test organisms, 
though, superclox and vitaclox showed a higher potency 
when compared with the standard controls. Alaclox 
produced significantly (P < 0.05) lower zones of inhi-
bitions compared to the other drugs (superclox and 
vitaclox) on S. aureus and S. pyogenes. However, 
significant differences (P = 0.007, P = 0.026, P = 0.050, P 
= 0.012) were observed between the zones of inhibitions 
of the test antibiotics and standard controls for the 3 
brands of ampiclox tested on all the test organisms 
except for K. pneumoniae. K. pneumoniae showed 
significantly (P = 0.184) high sensitivity comparable to the 
standard controls. There were also significant differences 
(P = 0.038, P = 0.038, P = 0.049, P = 0.025, P = 0.032) 
between the zones of inhibitions of test ciprofloxacin and 
standard controls and in the same vein, both brands of 
rifampicin (vitals and medifampi) produced significantly (P 
= 0.020, P = 0.038) lower zones of inhibitions on E. coli 
and S. pyogenes compared to the standard controls. This 
indicates that some of the ampiclox, ciprofloxacin and 
rifampicin sold in Calabar, Nigeria may be fake or 
adulterated and may not have contained the required 
ingredients needed to exert bacteriocidal or bacteriostatic 
(inhibitory) activity on the pathogens (Adejoh, 2000), 
which is a reflection of what goes on in many developing 
countries; in particular, in sub-Saharan Africa it is 
considerable and, within those countries, economically 
disadvantaged persons are most likely to contract 
communicable diseases and least likely to access 
appropriate treatment (Okeke et al., 2007; Okonko et al., 
2009a, b).  
The overall multiple responses of the organisms of the 
test organisms to different test antibiotics showed that for 
E. coli there were significant differences between the 
effectiveness/efficacy of ampiclox and ciprofloxacin (P = 
0.033), ampiclox and rifampicin (P = 0.000), ciprofloxacin 
and rifampicin (P = 0.000), gentamicin and rifampicin (P = 
0.001) and tetracycline and rifampicin (P = 0.0001). For 
K. pneumoniae, there were significant differences (P < 
0.05) between the mean zones of inhibitions showed by 
all the test antibiotics. P. aeruginosa responses in terms 
of their mean zones of inhibitions, showed significant 
differences (P < 0.05) between the effectiveness/efficacy 
of each antibiotics compared except between ampiclox 
and tetracycline (P = 0.766) as well as ciprofloxacin and 
gentamicin (P = 0.298) that showed comparable efficacies. 
In the same vein, for S. aureus, there were significant 
differences (P < 0.05) between the effectiveness/efficacy 
of ampiclox and other antibiotics except rifampicin (P = 
0.307) as well as, between ciprofloxacin and other test 
antibiotics except gentamicin (P = 0.062) and tetracycline 
(P = 0.855). In the case of S. pyogenes, there were 
significant (P < 0.05) differences between the effectiveness/ 
efficacy of each antibiotics compared except between 
ciprofloxacin and rifampicin (P = 0.437) and between 
gentamicin and tetracycline (P = 0.072).  
Similar observations have been made in a previous study 




by other scholars (Nwanze et al., 2007; Abubakar, 2009). 
In a study by Abubakar (2009), S. faecalis had a profile of 
70.7% susceptibility to ofloxacin and a susceptibility of 
less than 50.0% to gentamycin and tetracycline similar to 
the data presented by Nwanze et al. (2007). In a similar 
study by Kebira et al. (2009), 80% of the isolates were 
susceptible to gentamycin and ciproxin®. Adedeji and 
Abdulkadir (2009) reported gentamicin and ofloxacin to 
be the most active antibiotics against E. coli, S. 
saprophyticus, K. aerogenes, S. aureus, P. aeruginosa 
and S. faecalis. Their results of the antibiotic 
susceptibility tests showed that the isolates were 
generally highly susceptible to gentamicin (89%) and 
ofloxacin (60%). Also in a study by Abubakar (2009), P. 
aeruginosa had a susceptibility profile of 31.6% to 
ofloxacin, but not susceptible to gentamycin and 
tetracycline. P. aeruginosa maintains antibiotic resistance 
plasmids and are able to transfer these genes by 
bacterial processes of transduction and conjugation 
(Nwanze et al., 2007). Occurrence of multidrug resistant 
(MDR) P. aeruginosa from chronically infected patients 
has been a major reason for ultimate failure of antibiotic 
treatments. Early studies had shown that it is the 
environment in the lungs and the virulence factors that 
are the major reason for the MDR nature of this 
opportunistic pathogen. However, recent investigations 
have proved that it is the ability of increasing the rate of 
mutations that allow this organism to adapt to the 
heterogeneous and dynamic atmosphere of the lungs. 
These insights into the survival strategy of this organism 
will open ways to newer targets that are susceptible to 
new methods and allow us to tackle these infections 
(Seshadri and Chhatbar, 2009). 
Major concern however, in the case of P. aeruginosa, is 
the combination of its inherent resistance and ability to 
acquire resistance via mutations to all treatments leading 
to increasing occurrence of multi drug resistant strains 
(Henrichfreise et al., 2007b). Ability of P. aeruginosa to 
escape the effects of antibiotics is attributed by its 
capability of growing in microaerophilic environment as 
biofilms both of which reduce the efficiency of many 
antibiotics (Seshadri and Chhatbar, 2009). Resistance 
towards antimicrobial agents to survive in the lungs 
during frequent and prolonged treatments also requires 
great adaptive skills. Development of acquired resistance 
to antibiotics of different classes during antimicrobial 
therapy, which is rarely observed in acute infections, is a 
marked feature of chronic P. aeruginosa infections 
(Seshadri and Chhatbar, 2009). Our worst nightmare may 
even be more dreadful, with the occurrence of 
“panresistant” strains that arise due to the accumulation 
of multiple mechanisms of antibiotic resistance and are 
resistant to all antibiotics except polymyxins (Bonomo 
and Szabo, 2006; Seshadri and Chhatbar, 2009). 
The observations documented in current literature were 
compared and correlated with changes at the genetic 





the conditions in the lungs of chronically infected patients 
and major part of this adaptation comes from the 
mutations that take place in the genome of bacteria 
inside the lungs of the patients only (Henrichfreise et al., 
2007b; Seshadri and Chhatbar, 2009). However, the 
important role played by the selective pressure should 
not be neglected as it this condition which selects only 
those cells who have adapted to the conditions. This 
sequential continuous process of mutation and selection 
gives rise to the highly adapted strains so much so that 
sometimes the ability to survive in primary environment 
such as soil or distilled water is lost (Hogardt et al., 
2007). Intrinsic antibiotic resistance of P. aeruginosa 
accompanied by its ability to acquire resistance via 
mutations and adaption to the heterogeneous and 
dynamic environment of chronically infected lungs are 
major threats and reasons for the ultimate failure of the 
current antibiotic therapies in eradicating the infection 
from lungs (Seshadri and Chhatbar, 2009). New insights 
at molecular levels in the process of accumulating such 
beneficial mutations at faster rates, termed as hyper-
mutation have allowed us to understand the high 
acquired resistance of this opportunistic pathogen. Also, 
these understandings will allow us to develop new 
therapeutic strategies to combat chronic infections 
(Seshadri and Chhatbar, 2009). 
E. coli, worldwide, have developed resistance to 
antimicrobial agents and the phenomenon is increasing 
both in outpatients and hospitalized patients (Akram et 
al., 2007; Garcia et al., 2007). Among members of the 
enterobacteriaceae family, resistance to β-lactams has 
been reported to be associated with ESBL, which 
hydrolyze oxyimino beta-lactams like cefotaxime, 
ceftriaxone, ceftazidime and monobactams but have no 
effect on cephamycins, carbapenems and related 
compounds (Ullah et al., 2009). ESBL producing E. coli in 
this part of the world has been observed by several 
workers; its prevalence was variously reported from 28 to 
67% (Akram et al., 2007; Hammer et al., 2007; Mehrgan 
and Rahbar, 2008). Production of ESBL is frequently 
plasmid encoded and bears clinical significance. 
Plasmids responsible for ESBL production frequently 
carry genes encoding resistance to other drug classes also. 
Therefore, antibiotic options in the treatment of ESBL 
producing organisms are extremely limited (Paterson and 
Bonomo, 2005). Detection of ESBL production is 
important. One major concern is the spread of ESBL 
positive bacteria within hospitals, which may lead to 
outbreaks or to endemic occurrence (Ullah et al., 2009). 
Another concern is failure to treat infections caused by 
ESBL positive organisms, as therapeutic choices are 
limited (Paterson and Bonomo, 2005). It is necessary to 
investigate the prevalence of ESBL positive strains in 
hospitals so as to formulate a policy of empirical therapy 
in high risk units where infections due to resistant 
organisms are much higher (Ullah et al., 2009).  





habour series of antibiotic resistant genes which can be 
transferred to other bacteria horizontally (Depardieu et 
al., 2007; Leavitt et al., 2007; Lockhart et al., 2007). 
Epidemiologic surveillance of antimicrobial resistance is 
indispensable for empirically treating infections, imple-
menting resistance control measures and preventing the 
spread of antimicrobial-resistant microorganisms. The 
worldwide escalation in both community- and hospital-
acquired antimicrobial-resistant bacteria is threatening 
the ability to effectively treat patients, emphasizing the 
need for continued surveillance, more appropriate anti-
microbial prescription, prudent infection control and new 
treatment alternatives (Zhanel et al., 2008; Chikere et al., 
2008). The worldwide trend of empirically treating 
infections may not work well in Nigeria, because 
decreased susceptibility rates have been documented for 
majority of the common pathogens in various parts of the 
country. Some studies explained the higher resistance 
rates in tertiary hospitals especially where both inpatients 
and outpatients are used to collect data, as is the case in 
this study, to be due to those patients having more 
complicated UTIs and thus, exposed to more resistant 
flora, or may have failed previous therapy, all of which 
may account for the increased resistance observed 
(Abubakar, 2009). In a recent study in Lancet in 2001, out 
of 581 samples of 27 different drugs from pharmacies in 
Lagos and Abuja analyzed, 279 (48%) were found not to 
comply with the set pharmacopedia limits. Although some 
preparations contained no active ingredients, samples 
with either too much or too little of the active drug 
contents were identified and the manufacturers were from 
Belgium, China, Pakistan, Egypt, Germany, Switzerland, 
United Kingdom and Nigeria. Also, one of the cankerworms 
plaguing our country, Nigeria, in recent times is the 
menace of the sales of fake adulterated and substandard 
drugs which has eaten deep into the fabric of our society 
like a bad ulcer (Popoola, 2001). 
This study showed that the efficacy of antibiotics sold in 
Nigeria is poor with reference to the active ingredients 
used. In this study, the observed efficacy and quality of 
some of the antibiotics sold in Nigeria differ in their efficacy 
or potency according to their brands or manufacturers. 
Some show a higher efficacy and some a low efficacy 
when compared to the standards used. In accordance 
with the assertion of Abubakar (2009), some of the drugs 
were sensitive, but a good number have also lost their 
usefulness. These differences in efficacy among brands 
of some antibiotics constitute a grave danger to health. 
This study has also shown that about 20% of the brands 
of antibiotics studied had reduced potency against the 
test bacteria used in this study. The data presented in 
this investigation are similar to those obtained in other 
Nigerian cities of Kano, Yola, Jos, Lafia, Abuja, Enugu, 
Port-Harcourt, Calabar, Abeokuta, Lagos and Ibadan and 
have shown the changing pattern in the types of organisms 
causing infections  and  their  resistance  to  many  of  the  
commonly available antibiotics, thus leading to the use of 




newer and more costly agents (Ako-Nai et al., 2005; 
Nwanze et al., 2007; Kolawale et al., 2009; Okesola and 
Oni, 2009; Abubakar, 2009; Okonko et al., 2009a,b; 
Nkang et al., 2009a, b). Indiscriminate use and under 
dosage have resulted in the emergence of drug resistant 
strains in Nigeria (Akpan, 1992; Okonko et al., 2009a, b). 
Resistance due to over use and adulteration of the 
antibiotics has also been reported. Misuse of drugs in a 
hospital can influence further misuse outside the hospital. 
All the isolates in this study showed resistance to at least 
1-3 different antibiotics, indicating the presence of strong 
selective pressures from the antibiotics in the community. 
The use of antibiotics within the hospital has also become 
a cause for concern as they are commonly prescribed 
without sound justification thus, calling to question the 
professional competences of the attending healthcare 
givers (Fehintola, 2009). Most hospitals in Nigeria lack 
guidelines for the use of antibiotics and the country lacks 
any antibiotics and indeed any drug policy (Fehintola, 
2009). 
Previous studies have reported that horizontal gene 
transfer is a factor in the occurrence of antibiotic resistance 
in clinical isolates and suggested that the high prevalence 
of resistance to a particular antibiotic does not always 
reflect antibiotic consumption as previously suggested by 
other scholars (Ako-Nai et al., 2005; Nwanze et al., 2007; 
Abubakar, 2009). Notwithstanding the knowledge of 
contribution of misuse of antibacterial agents to the 
development and spread of drug resistance, there 
appears to be total lack of efforts at controlling the use of 
this life-saving medication amongst the general populace 
particularly in Nigeria and many other countries of Africa 
(Fehintola, 2009). Rational and optimal use of antibiotics 
should be predicated on the right information with respect 
to epidemiology; ensuring the training and retraining of 
prescribers with respect to proper orientation to the use 
of antibiotics; provision of essential laboratory facilities for 
bacteriological diagnosis and controlling information and 
marketing in such way as to ensure promotion and 
availability of the essential antibiotics. The unbridled 
advertisement, promotion and sale of antibiotics as 
currently practiced in Nigeria can only encourage anti-
bacterial drug resistance and the attendant threat from 
bacteria (Akande and Ologe, 2007; Fehintola, 2009). The 
zones of inhibitions shown by these brands of antibiotics 
against the test organisms indicate their potencies 
(Cheesbrough, 2006). The potencies of course have to 
do with the active ingredients contained in each of the 
antibiotics since the test were compared to the standards. 
In line with the assertions of Winstanley et al. (1997) and 
Abubakar (2009), even though susceptibility pattern 
shown in this study emphasizes the need for in vitro 
sensitivity reports before initiation of antibiotic therapy, it 
must not be forgotten that in vitro antimicrobial sensitivity 
reports serve only as guide and that conditions in vivo 
may be quite different. The data presented in this  and  in  
previous studies may be  of  immense  value  for  use   to 




determine trend in antimicrobial sensitivities, to formulate 
local antibiotic policies to compare local with national and 
international data and above all, to assist clinicians in the 
rational choice of antibiotic therapy and to prevent 
misuse, or over use of antibiotics. The data obtained in 
this study shows that the bacteria causing most community 
and nosocomial infections are still susceptible to anti-
microbial agents routinely used in the hospital though this 
is changing. Although the disc diffusion method was used 
to assess sensitivity and resistance and can be 
correlated clinically, further investigations employing the 
MIC method will be needed to obtain more reliable results 
(Abubakar, 2009). 
Other factors, though not tested in this study, that could 
have affected their potencies include storage procedure, 
temperature, adulteration, humidity, expiring dates, 
pathophysiological state of the patient, natural history of 
the infection, presence of R-factor, age of patient, etc. 
Also, the widespread counterfeiting of these antibiotics, 
excessive decomposition of active ingredient as a result 
of exposure to high temperature and humidity, and poor 
quality assurance during manufacturing which are not 
exceptions, were not investigated; however, the differences 
in efficacy among brands of the antibiotics constitute a 
grave danger to health. There is therefore an urgent need 
for all pharmaceutical products manufacturers to make 
sure that the manufacturing of antibiotics is undertaken in 
accordance with the basic principles of good manufacturing 
practices (GMP). They should be sold and distributed by 
pharmaceutical medical representatives. The pharma-
ceutical inspectorate division of the Federal Ministry of 
Health in conjunction with National Agency for Food and 
Drug Administration and Control (NAFDAC) should be 
empowered to arrest and prosecute hoodlums and inspect 
these antibiotics accordingly. The label on the package 
and the leaflets in the package should provide instruction 
for the use of the antibiotic and its potential adverse 
reactions. The antibiotic should indicate the name dosage 
of the product, date of manufacture, identification number, 
formulation, batch number, quality assurance and control 
provisions, name of manufacturer and supplier (Immaculata 
and Abraham, 1990).  
Moreover, the application of some industrial and good 
manufacturing practices should be applied (Connor and 
Berlin, 2000). These include that: (1) all equipment, 
including sterilizers, air filtration and water treatment 
systems should be subject to planned maintenance, 
validation and monitoring; (2) the industrial environment 
should be cleaned frequently and thoroughly in accordance 
with the written programme approved by the quality 
control department; (3) the use of nutrient media that 
support microbial growth in trials to stimulate aseptic' 
operations (Sterile media fills, "broth fills") is a valuable 
part of the overall validation of an aseptic process and 
should be employed; (4) the microbiological contamination 
of starting materials should be minimal and the "bioburden" 
should be  monitored  before  sterilization  and  (5)   each  
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